Acquisition leverage ReachBio has been acquired by Discovery Life Sciences, expanding its cell biology capabilities and resources. This presents a cross-sell opportunity to Discovery’s existing client base in biospecimens and biomarkers, particularly for programs needing primary cell biology expertise and toxicology, immunology, and biomarker development.

Specialized expertise Strong focus on hematopoietic primary cell systems and thrombocytopenia risk assessment positions ReachBio as a partner for drug development programs targeting blood-related toxicities and hematologic endpoints. This can be offered alongside broader discovery services to improve translational relevance.

Platform capabilities Existing platforms such as cellPrism and drug screening capabilities indicate a track record in predictive toxicology, efficacy testing, and high-throughput-style screening. These capabilities can be bundled with biomarker selection and flow cytometry services to support early- to mid-stage programs.

Strategic fit With modest revenue and a small team, ReachBio can complement larger CROs by providing specialized primary cell assays and mechanistic insights. This creates a potential channel for Discovery Life Sciences to expand service depth in cell-based assays and mechanistic toxicology offerings.

Market alignment Industry peers in the life sciences CRO space emphasize hematology, toxicology, and biomarker services. Position ReachBio as a niche provider within Discovery’s portfolio to attract pharmaceutical developers seeking predictive primary cell data and clinically relevant thrombocytopenia risk assessments.